DCOY
Decoy Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.69
−6.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 8.5M | 8.5M | — | — | — |
| Gross Profit | (8.5M) | (8.5M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 2.2M | 368.2K | 770.0K | 7.2M | 15.8M |
| SG&A Expense | 4.1M | 3.7M | 5.0M | 5.7M | 7.1M |
| General & Admin Expense | 4.1M | 3.7M | 5.0M | 5.7M | 7.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 8.9M |
| Total Operating Expenses | 6.3M | 4.1M | 5.7M | 12.9M | 31.8M |
| Cost and Expenses | 14.8M | 12.6M | 5.7M | 12.9M | 31.8M |
| Operating Income (EBIT) | (14.8M) | (12.6M) | (5.7M) | (12.9M) | (31.8M) |
| Non-Operating | |||||
| Interest Income | 71.8K | 95.5K | 158.5K | 352.3K | 218.73 |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 71.8K | 95.5K | 158.5K | 352.3K | 218.73 |
| Other Non-Op Income/Expense | 394.9K | 95.5K | 158.5K | 352.3K | 233.2K |
| Non-Operating Income (excl Interest) | (394.9K) | (95.5K) | (158.5K) | (352.3K) | (8.9M) |
| EBT (Pre-Tax Income) | (14.4M) | (12.5M) | (5.6M) | (12.5M) | (31.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (14.4M) | (12.5M) | (5.6M) | (12.5M) | (31.6M) |
| Earnings from Cont. Ops | (14.4M) | (12.5M) | (5.6M) | (12.5M) | (31.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.4M) | (12.5M) | (5.6M) | (12.5M) | (31.6M) |
| Per Share | |||||
| Basic EPS | ($29.09) | ($25.99) | ($86.92) | ($461.04) | ($1,785.33) |
| Diluted EPS | ($29.09) | ($25.99) | ($86.92) | ($461.04) | ($1,785.33) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 531968 | 481587 | 64147 | 27205 | 17704 |
| Diluted Shares Outstanding | 531968 | 481587 | 64147 | 27205 | 17704 |
| Profitability Metrics | |||||
| EBITDA | (14.4M) | (12.5M) | (5.6M) | (12.5M) | (23.0M) |
| D&A | 10.9K | 7.2K | 4.4K | 10.1K | 6.7K |
| EBIT | (14.4M) | (12.5M) | (5.6M) | (12.5M) | (23.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026